Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | MTOR | P42345 | 3/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL431120 | 0.85 | MTOR (0.47) | PIK3CAMTORPIK3R1SMN1; SMN2MAPK1 | |
| SCHEMBL10198825 | 0.74 | CHEK1 (0.50) | PIK3CAMTORPIK3R1SMN1; SMN2KDM4E | |
| SCHEMBL3326043 | 0.73 | LMNA (0.58) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL12773823 | 0.71 | CHEK1 (0.55) | PIK3CAMTORSMN1; SMN2LMNAKDM4E | |
| SCHEMBL14259010 | 0.69 | LMNA (0.56) | SMN1; SMN2MAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL4362437 | 0.66 | MTOR (0.69) | PIK3CAMTORPIK3R1 | |
| SCHEMBL21135295 | 0.66 | STAT3 (0.50) | PIK3CAMTORPIK3R1KDM4ESTAT3 | |
| SCHEMBL3752841 | 0.65 | PIK3CA (0.49) | PIK3CAMTORPIK3R1STAT3JAK2 | |
| SCHEMBL21135294 | 0.65 | MAPT (0.44) | PIK3CAMTORSTAT3PIK3CG | |
| SCHEMBL3931130 | 0.64 | PIK3CA (0.53) | PIK3CAMTORPIK3R1PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | SYNTA PHARMACEUTICALS CORP. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7410990-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | SYNTA PHARMACEUTICALS CORP. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20070027151-A1 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-01 | — | — | US | disclosed |
| US-7122665-B2 | Heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1556140-A4 | NOVEL COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-1556140-A2 | NOVEL COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20040198725-A1 | A bi-heterocyclic compound e.g 3-methoxyphenyl)-{6-Morpholin-4-yl-2-[2-(pyridin-2-yloxy)-ethoxy]-9H-purin-8-yl}-amine or other derivatives useful for treating an interleukin-12 overproduction-related disorder such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis or diabetes | SYNTA PHARMACEUTICALS CORP. | 2004-10-07 | — | — | US | disclosed |
| WO-2004035740-A2 | AROMATIC BICYCLIC HETEROCYLES TO MODULATE 1L - 12 PRODUCTION | SYNTA PHARMACEUTICALS CORP. (US) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058297-A1 | Heterocyclic Compounds For Preventing And Treating Disorders Associated With Excessive Bone Loss | BRCA1, VHL, ESR1 | PIK3CA 386/4885MTOR 780/4885PIK3R1 1957/4885 |
| US-20040198725-A1 | A bi-heterocyclic compound e.g 3-methoxyphenyl)-{6-Morpholin-4-yl-2-[2-(pyridin-2-yloxy)-ethoxy]-9H-purin-8-yl}-amine or other derivatives useful for treating an interleukin-12 overproduction-related disorder such as rheumatoid arthritis, sepsis, Crohn's disease, multiple sclerosis, psoriasis or diabetes | MSR1, NGFR, NR0B1 | PIK3CA 4824/4885MTOR 2881/4885PIK3R1 1895/4885 |
| US-20100120722-A1 | HETEROCYCLIC COMPOUNDS FOR PREVENTING AND TREATING DISORDERS ASSOCIATED WITH EXCESSIVE BONE LOSS | BRCA1, VHL, ESR1 | PIK3CA 386/4885MTOR 780/4885PIK3R1 1957/4885 |
| US-20070027151-A1 | Heterocyclic compounds | NRAS, OXER1, HCRTR2 | PIK3CA 3455/4885MTOR 1741/4885PIK3R1 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.